Figure 1.

ELFN2 Is Overexpressed due to Promoter Hypomethylation and Is Correlated with a Poor Outcome in Astrocytoma

(A) Schematic diagram of the CpG dinucleotides within the ELFN2 promoter. The nucleotide number is relative to the transcription start site of ELFN2. The red line indicates the region that was tested with BSP, and the blue line indicates the region that was detected with MSP. (B) BSP of the upstream regulatory region of ELFN2 was performed for the representative tissues (N, normal brain tissue; T, GBM sample). (C) The methylation status of ELFN2 in the GBM samples (n = 50) and normal brain tissues (n = 10) was detected using BSP. The data are presented as the means ± SEM of three independent experiments. *p < 0.05. (D) qRT-PCR was used to detect the expression of ELFN2 in GBM cells and primary GBM cells. The data are presented as the means ± SEM of three independent experiments. (E) Western blotting was used to detect the expression of ELFN2 in GBM cells and primary GBM cells. (F) The methylation status of ELFN2 in GBM cell lines was detected by MSP. U, unmethylated primer; M, methylated primer. (G) Kaplan-Meier curve analysis of 50 astrocytoma patients stratified by ELFN2 methylation. Astrocytoma patients with ELFN2 methylation have a better overall survival. (H) Kaplan-Meier curve analysis of 50 astrocytoma patients stratified by ELFN2 expression. Astrocytoma patients with low ELFN2 expression have a better overall survival.